# Mark Clemens M.D. – FDA 483, Aug 6, 2026

Source: https://www.keypedia.com/records/483/mark-clemens-md/7f6a05d9-bc74-4c5e-8e58-27886c257162

> FDA 483 for Mark Clemens M.D. on August 06, 2026. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Mark Clemens M.D.
- Inspection Date: 2026-08-06
- Product Type: other
- Office Name: Dallas District Office
- Summary: An FDA inspection of Mark Clemens M.D. in Houston, TX, a clinical investigator, revealed significant deviations from investigational plans and applicable FDA regulations. The firm failed to report serious adverse events to the sponsor within the required timeframe and did not return explanted investigational devices for evaluation as mandated by protocol. These findings indicate a moderate level of non-compliance in clinical trial conduct.

## Related Officers

- [Jasmine Y. Wang](https://www.keypedia.com/people/jasmine-y-wang/e23c7335-477c-4671-8dcc-72e9149d424e)

Company: https://www.keypedia.com/companies/mark-clemens-md/14eb7ca1-96d1-4e1b-b0f2-8ef0d19c53f8

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9